Leucine zipper-based compositions and methods of use

Patent metadata

Field	Value
Publication number	US-12509498-B2
Application number	US-202117176533-A
Country	US
Kind code	B2
Filing date	Feb 16, 2021
Priority date	Aug 16, 2018
Publication date	Dec 30, 2025
Grant date	Dec 30, 2025

Abstract

The presently disclosed subject matter provides compositions and systems for cell-based immunotherapy. In certain non-limiting embodiments, the system comprises a membrane-bound polypeptide and at least one soluble polypeptide that is capable of dimerizing with the membrane-bound polypeptide.

First claim

What is claimed is:

1 . A system, comprising:
a) a membrane-bound polypeptide comprising:
i) a transmembrane domain,
ii) an intracellular domain, and
iii) an extracellular domain that comprises a first dimerization domain and a second dimerization domain that is capable of dimerizing with the first dimerization domain, and
b) a soluble polypeptide comprising:
i) a third dimerization domain that is capable of dimerizing with the first dimerization domain, and
ii) an antigen binding domain that binds to an antigen,
wherein each of the first dimerization domain, the second dimerization domain, and the third dimerization domain comprises a leucine zipper domain, the first dimerization domain and the second dimerization domain are an orthogonal pair, and the first dimerization domain and the third dimerization domain are an orthogonal pair.

2 . The system of claim 1 , wherein the antigen is selected from the group consisting of a tumor antigen, a pathogen antigen, an immune checkpoint molecule, an activating receptor, and a biomarker of a hematopoietic lineage cell.

3 . The system of claim 2 , wherein the antigen is a tumor antigen.

4 . The system of claim 3 , wherein the tumor antigen is selected from the group consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, VpreB, CD30, CD33, CD38, CD40, CD44v6, CD70, CD79a, CD70b, CLL-1/CLEC12A, CD123, IL-3R complex, TIM-3, BCMA, TACI, SLAMF7, CD244, Epcam, E-cadherin, B7-H3, and B7-H4.

5 . The system of claim 2 , wherein the antigen is an immune checkpoint molecule.

6 . The system of claim 5 , wherein binding of the antigen binding domain to the immune checkpoint molecule is capable of blocking an immune checkpoint signal in an immunoresponsive cell.

7 . The system of claim 2 , wherein the antigen is a biomarker of a hematopoietic lineage cell.

8 . The system of claim 7 , wherein the biomarker of a hematopoietic lineage cell is selected from the group consisting of CD3, CD16, CD33, c-Kit, CD161, CD19, CD20, VpreB, luteinizing hormone receptor (LHCGR), CD123, IL-3R complex, and CLEC12A/CLL-1.

9 . The system of claim 7 , comprising at least four soluble polypeptides, wherein the antigen binding domain of each soluble polypeptide binds to a different biomarker of a hematopoietic lineage cell.

10 . The system of claim 9 , comprising a first soluble polypeptide that binds to CD3, a second soluble polypeptide that binds to CD19, a third soluble polypeptide that binds to CD161 and a fourth soluble polypeptide that binds to c-Kit.

11 . The system of claim 1 , wherein the antigen is an activating receptor.

12 . The system of claim 11 , wherein binding of the antigen binding domain to the activating receptor is capable of activating an antigen presenting cell (APC), or the activating receptor is selected from the group consisting of CD40, Toll Like Receptors (TLRs), FLT3, RANK, and GM-CSF receptor.

13 . The system of claim 12 , wherein the APC is a professional APC, a non-professional APC, or a cell of the myeloid lineage.

14 . The system of claim 13 , wherein
a) the professional APC is selected from the group consisting of dendritic cells, macrophages, and B cells; or b) the cell of myeloid lineage is selected from the group consisting of dendritic cells, macrophages, and monocytes.

15 . The system of claim 1 , wherein the extracellular domain of the membrane-bound polypeptide further comprises:
a) a linker between the first dimerization domain and the second dimerization domain; b) a spacer/hinge domain between the first dimerization domain and the transmembrane domain; c) a co-stimulatory ligand; or d) a dominant negative form of a molecule.

16 . The system of claim 15 , wherein
a) the linker comprises the amino acid sequence set forth in SEQ ID NO: 3; b) the spacer/hinge domain comprises:
i) an epitope recognized by an antibody, wherein binding of the antibody to the epitope mediates depletion of a cell comprising the membrane-bound polypeptide; or
ii) a Thy1.1 molecule, a CD20 mimotope, or a truncated EGFR molecule (EGFRt);
c) the co-stimulatory ligand is selected from the group consisting of a tumor necrosis factor (TNF) family member and an immunoglobulin (Ig) superfamily member; or d) the molecule is selected from the group consisting of an inhibitor of an immune checkpoint molecule, a tumor necrosis factor receptor superfamily (TNFRSF) member, and a transforming growth factor beta (TGFβ) receptor.

17 . The system of claim 16 , wherein
a) the TNF family member is selected from the group consisting of 4-1BBL, OX40L, CD70, GITRL, CD40L, and CD30L; b) the Ig superfamily member is selected from the group consisting of CD80, CD86, and ICOSLG; c) the immune checkpoint molecule is selected from the group consisting of PD-1, CTLA-4, B7-H3, B7-H4, BTLA, TIM-3, LAG-3, TIGIT, LAIR1, CD200, CD200R, HVEM, 2B4, CD160, and Galectin9; or d) the TNFRSF member is selected from the group consisting of Fas, a Tumor necrosis factor receptor, OX40, CD40, CD27, CD30, and 4-1BB.

18 . The system of claim 1 , wherein the intracellular domain of the membrane-bound polypeptide comprises one or more immune activating molecules.

19 . The system of claim 1 , wherein the intracellular domain of the membrane-bound polypeptide does not comprise one or more immune activating molecules.

20 . The system of claim 1 , wherein the soluble polypeptide and the membrane-bound polypeptide are:
a) capable of forming a dimer when expressed from the same cell, and b) are not capable of forming a dimer when expressed from different cells due to the dimerization between the first dimerization domain and the second dimerization domain of the membrane-bound polypeptide.

21 . The system of claim 1 , wherein the intracellular domain of the membrane-bound polypeptide comprises a CD3-ζ domain or a costimulatory domain.

22 . The system of claim 1 , further comprising a suicide molecule.

23 . The system of claim 22 , wherein the suicide molecule is an inducible Caspase 9 polypeptide (iCasp9).

24 . The system of claim 1 , wherein the membrane-bound polypeptide and/or the soluble polypeptide further comprises a tag or a mimotope recognized by an antibody, wherein binding of the antibody to the mimotope mediates depletion of a cell comprising the membrane-bound polypeptide.

25 . The system of claim 24 , wherein
a) the tag comprises an epitope tag that is recognized by a first antibody or an affinity tag that binds to a substrate; or b) the mimotope is CD20.

26 . The system of claim 25 , wherein
a) the epitope tag is selected from the group consisting of a Myc-tag, a HA-tag, a Flag-tag, a V5-tag, and a T7-tag; or b) the affinity tag is selected from the group consisting of a His-tag, a Strep-tag, an E-tag, and a streptavidin binding protein tag (SBP-tag).

27 . The system of claim 1 , wherein the antigen binding domain comprises a single-chain variable fragment (scFv), a soluble ligand, a cytokine, and a non-scFv-based antigen recognition motif.

28 . The system of claim 6 , wherein the immune checkpoint molecule is selected from the group consisting of PD-L1, CD200, B7-H3, B7-H4, HVEM, Galectin9, PD-1, CTLA-4, CD200R, TIM-3, Lag-3, and TIGIT.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• James Scott E
• Van Den Brink Marcel R M
• Jahn Lorenz

Classifications

• C07K14/70596

  Molecules with a "CD"-designation not provided for elsewhere · CPC title

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C07K14/705

  Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title

• A61K40/4221

  CD20 · CPC title

• A61K40/4211

  CD19 or B4 · CPC title